Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer

Breast Journal

Volumn 16, Issue 1, 2010, Pages 66-72

  Metro, Giulio ^a   Giannarelli, Diana ^a   Gemma, Donatello ^b   Lanzetta, Gaetano ^c   Ciccarese, Mariangela ^d   Papaldo, Paola ^a   Gamucci, Teresa ^b   Lorusso, Vito ^d   Mottolese, Marcella ^a   Magnolfi, Emanuela ^b   Cognetti, Francesco ^a   Fabi, Alessandra ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Umberto I Hospital   (Italy)

^c Division of Medical Oncology   (Italy)

^d VITO FAZZI HOSPITAL   (Italy)

Author keywords

Disease progression; HER 2; Metastatic breast cancer; Trastuzumab

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; REMISSION INDUCTION; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77249179256     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00849.x     Document Type: Article

References (21)

1. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/- neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007;19:56-62.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
3. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265- 74.
4. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive hormone-receptor positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, doi: 10.1200/JCO.2009.23.3734.
5. Dinh P, de Azambuja E, Piccart-Gebhart MJ. Trastuzumab for early breast cancer: current status and future directions. Clin Adv Hematol Oncol 2007;5:707-17.
6. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reac- tive drugs. Oncogene 1998;17:2235-49.
7. Yeon CH, Slamon D, Patel R, et al. Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT). Proc Am Soc Clin Oncol 2004;22:680 (abstract).
8. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-70.
9. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemo- therapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49.
10. Tripathy D, Hassan S, Verma U, Gurnani P, Nandi A, Rosenblatt K. Phenotypic and proteomic alterations of acquired trastuzumab resistance. Proc Am Soc Clin Oncol 2005;23:3121 (abstract).
11. Fujimoto-Ouchi K, Sekiguchi F, Mori K. Preclinical study of continuous administration of trastuzuamb as combination therapy after disease progression with trastuzumab monotherapy. Proc Am Assoc Cancer Res 2005;46:5062 (abstract).
12. Fabi A, Metro G, Ferretti G, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008;17:499-505.
13. Mottolese M, Fabi A, Nistico C, et al. PTEN and phospho- MAP kinase are indipendent predictors of response only in meta- static breast cancer patients treated with trastuzumab plus chemotherapy as first-line option. Breast Cancer Res Treat 2006;100:S139-40 (abstract 3046).
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
15. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus cape- citabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
16. von Minckwitz G, du Bois A, Schmidt M, et al. Trast- uzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/ breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
17. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965-72.
18. Montemurro F, Viale G, Donadio M, et al. Retrospective evaluation of clinical outcomes in HER-2 positive advanced breast cancer patients progressing on trastuzumab-based therapy in the pre-lapatinib era. Breast Cancer Res Treat 2007;106:S185 (abstract 4057).
19. Extra JM, Antoine EC, Vincent-Salomon A, Bergougnoux L, Campana F, Namer M. Favourable effect of continued trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study. Breast Cancer Res Treat 2006;100:S102 (abstract 2064).
20. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003;4:120-5.
21. Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00820222 (last accessed May 26, 2009).